Source: Eur Respir J, 50 (1) 1700311; 10.1183/13993003.00311-2017
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Jeffrey Hafkin, Norbert Hittel, Alexandra Martin, Rajesh Gupta. Early outcomes in MDR-TB and XDR-TB patients treated with delamanid under compassionate use. Eur Respir J, 50 (1) 1700311; 10.1183/13993003.00311-2017

Member's Comments

No comment yet.

Related content which might interest you: Impact of XDR-TB on treatment outcome of MDR-TB patients with standardized regimens Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008 Experience of Bedaquiline use in treatment of XDR-TB patients Source: International Congress 2017 – TB: diagnosis, severity and practical management Year: 2017 Treatment effectiveness and predictors of poor outcome in MDR-TB and XDR-TB Source: Breathe 2008; 6: 161 Year: 2009 Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of multidrug-resistant tuberculosis Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016 Effectiveness and safety of six month chemotherapy course of XDR TB including bedaquiline and linezolid Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016 MDR-TB and XDR-TB: drug resistance and treatment outcomes Source: Eur Respir J 2009; 34: 778 Year: 2009 Impact of pre-treatment duration by first line drugs on treatment outcomes of patients with MDR-TB Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Poor treatment outcomes of XDR-TB patients in resource-limited settings Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012 Evaluation of failures treated with linezolid-containing regimen for extensively drug-resistant tuberculosis (XDR-TB) Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Treatment outcomes for XDR TB patients with surgery Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis Year: 2007 Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB Source: Eur Respir J 2016; 47: 1235-1243 Year: 2016 Final treatment outcomes of multidrug- and extensively drug-resistant tuberculosis patients in Latvia receiving delamanid-containing regimens Source: Eur Respir J, 50 (5) 1701105; 10.1183/13993003.01105-2017 Year: 2017 The experience of complex treatment of XDR-TB patients Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance Year: 2009 The incidence of multi drug resistant tuberculosis among patients receiving standardized treatment regimen for suspected MDR-TB Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012 Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid Source: Eur Respir J 2015; 45: 1498-1501 Year: 2015 Factors affecting the efficacy of treatment of MDR/XDR TB patients receiving bedaquiline Source: International Congress 2019 – Tuberculosis: a public health approach Year: 2019 MDR-TB treatment in prison setting Source: Annual Congress 2007 - Tuberculosis control in the penitentiary and civilian sector Year: 2007 All-oral longer regimens are effective for the management of multidrug-resistant tuberculosis in high-burden settings Source: Eur Respir J, 59 (1) 2004345; 10.1183/13993003.04345-2020 Year: 2022 Linezolid in the treatment of patients with MDR TB and XDR TB Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 Long-term treatment outcomes in multidrug-resistant tuberculosis (MDR-TB) Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis Year: 2007